Results 101 to 110 of about 1,763 (188)

Efficacy of radiotherapy in stabilization of oligoprogressive lesions of malignant melanoma treated with immunotherapy

open access: yesReports of Practical Oncology and Radiotherapy
BACKGROUND: This study aims to evaluate the effectiveness of radiotherapy (RT) in stabilizing oligoprogressive disease (OPD) in melanoma patients undergoing immunotherapy.
Martin Palkovsky   +7 more
doaj   +1 more source

Frequency and Prognostic Impact of Local Ablation Therapy for Oligoprogression in Non‐Small Cell Lung Cancer

open access: yesThoracic Cancer
Background During the systemic treatment of patients with non‐small cell lung cancer (NSCLC), oligoprogression (OP), a condition in which most lesions remain controlled while a few progress or develop, has recently attracted attention.
Daisuke Morinaga   +16 more
doaj   +1 more source

Imaging as a Surgical Decision System in Modern Gynecologic Oncology

open access: yesDiagnostics
Imaging traditionally supports gynecologic oncology through diagnosis, staging, and estimation of resectability. Contemporary treatment, however, requires longitudinal decisions about which lesion matters, when local intervention is justified, and which ...
Angel Yordanov   +5 more
doaj   +1 more source

IBS01.02 Strategies Treatment After Oligoprogression [PDF]

open access: yesJournal of Thoracic Oncology, 2019
F. Cappuzzo, L. Landi
openaire   +1 more source

Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter

open access: yes, 2017
Purpose To assess the association between colorectal cancer (CRC) histology, dose, and local failure (LF) after stereotactic ablative radiation therapy (SABR) for pulmonary metastases, and to describe subsequent cancer progression, change of systemic ...
Soliman, Hany   +17 more
core   +1 more source

Oligometastatic NSCLC: Current Perspectives and Future Challenges [PDF]

open access: yes
Oligometastatic non-small cell lung cancer (NSCLC) represents a separate entity with a different biology and prognosis compared to stage IV NSCLC. Challenges range from the very definition of oligometastatic disease to the timing and techniques of local ...
Zanchetta C.   +5 more
core   +1 more source

Adding Docetaxel to Tepotinib to Overcome Oligoprogression in MET Exon 14 Skipping–Mutated NSCLC When Local Therapy Is Unfeasible: A Case Report

open access: yesCase Reports in Oncological Medicine
Trial Registration: ClinicalTrials.gov identifier ...
David Sánchez García   +6 more
doaj   +1 more source

Efficacy and safety of radiotherapy to delay second-line systemic therapy in patients with oligoprogressive hepatocellular carcinoma: study protocol of a multicentre, single-arm, phase II trial

open access: yesTherapeutic Advances in Medical Oncology
Background: Hepatocellular carcinoma (HCC) is a highly aggressive cancer with a paucity of efficacious treatment options, particularly in advanced stages following first-line systemic therapy (FLST).
Haohua Wang   +10 more
doaj   +1 more source

External validation of a genomic signature for oligometastatic non-small cell lung cancer

open access: yes
Objective: We previously presented a genomic signature predictive of both oligometastatic disease state and oligoprogression in patients with brain metastases.
Xing, Fei   +17 more
core  

Home - About - Disclaimer - Privacy